CN115120606A - 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法 - Google Patents

治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法 Download PDF

Info

Publication number
CN115120606A
CN115120606A CN202210682855.1A CN202210682855A CN115120606A CN 115120606 A CN115120606 A CN 115120606A CN 202210682855 A CN202210682855 A CN 202210682855A CN 115120606 A CN115120606 A CN 115120606A
Authority
CN
China
Prior art keywords
cangrelor
pci
administration
patients
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210682855.1A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·阿尔库吕斯-米恩韦尔
S·斯凯伊安内克
J·普拉茨
D·J·施耐德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/792,056 external-priority patent/US9427448B2/en
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CN115120606A publication Critical patent/CN115120606A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202210682855.1A 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法 Pending CN115120606A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13/792,056 US9427448B2 (en) 2009-11-11 2013-03-09 Methods of treating, reducing the incidence of, and/or preventing ischemic events
US13/792,056 2013-03-09
US201361815735P 2013-04-25 2013-04-25
US61/815,735 2013-04-25
CN201380076382.XA CN106102750A (zh) 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法
PCT/US2013/043136 WO2014143107A1 (en) 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380076382.XA Division CN106102750A (zh) 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法

Publications (1)

Publication Number Publication Date
CN115120606A true CN115120606A (zh) 2022-09-30

Family

ID=51537409

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380076382.XA Pending CN106102750A (zh) 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法
CN202210682855.1A Pending CN115120606A (zh) 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201380076382.XA Pending CN106102750A (zh) 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法

Country Status (10)

Country Link
EP (2) EP2964233B1 (enExample)
JP (3) JP6247708B2 (enExample)
CN (2) CN106102750A (enExample)
AU (1) AU2013381855B2 (enExample)
BR (1) BR112015022070B1 (enExample)
CA (1) CA2904523C (enExample)
EA (1) EA034550B1 (enExample)
ES (1) ES2904256T3 (enExample)
PL (1) PL2964233T3 (enExample)
WO (1) WO2014143107A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022070B1 (pt) * 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor
CN110740736A (zh) * 2017-06-23 2020-01-31 奇斯药制品公司 预防体-肺动脉分流术血栓形成的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110112030A1 (en) * 2009-11-11 2011-05-12 The Medicines Company Methods of treating or preventing stent thrombosis
CN102089035A (zh) * 2008-05-13 2011-06-08 医药公司 抗血小板治疗中血小板抑制的维持

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL175623B1 (pl) 1993-02-10 1999-01-29 Astra Pharma Prod N-alkilo-2-podstawione analogi ATP, sposób ich wytwarzania i kompozycja farmaceutyczna je zawierająca
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20100297675A1 (en) * 2008-11-24 2010-11-25 Huayun Deng Substrate and method for culturing breast cells
EP2384196B1 (en) * 2008-12-30 2017-09-13 Johansson, Pär Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
EP2443120B1 (en) * 2009-06-16 2016-11-02 RSPR Pharma AB Crystalline form of pemirolast
BR112015022070B1 (pt) * 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089035A (zh) * 2008-05-13 2011-06-08 医药公司 抗血小板治疗中血小板抑制的维持
US20110112030A1 (en) * 2009-11-11 2011-05-12 The Medicines Company Methods of treating or preventing stent thrombosis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS: "NCT01766466-Version 4", pages 1 - 8, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/study/NCT01766466?intr=%20cangrelor%20ticagrelor&rank=1&tab=history&a=4> *
NIHAR R. DESAI等: "The State of Periprocedural Antiplatelet Therapy After Recent Trials", 《JACC: CARDIOVASCULAR INTERVENTIONS》, vol. 3, no. 6, pages 571 - 583, XP029643374, DOI: 10.1016/j.jcin.2010.04.008 *
ROBERT F. STOREY等: "Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes", 《JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY》, vol. 50, no. 19, pages 1852 - 1856 *
李小鹰主编: "《阿司匹林临床手册 医师版100问》", vol. 2, 31 May 2010, 人民军医出版社, pages: 119 - 120 *
林菁华主编: "《内科医生实用装备手册》", vol. 1, 31 May 2011, 中山大学出版社, pages: 39 *
王慕一等主编: "《血栓病的基础与临床》", vol. 1, 31 March 1996, 辽宁科学技术出版社, pages: 197 *

Also Published As

Publication number Publication date
CN106102750A (zh) 2016-11-09
EA034550B1 (ru) 2020-02-19
CA2904523A1 (en) 2014-09-18
JP2019178177A (ja) 2019-10-17
EP2964233B1 (en) 2021-12-15
JP6840197B2 (ja) 2021-03-10
WO2014143107A1 (en) 2014-09-18
JP2018002739A (ja) 2018-01-11
EP2964233A1 (en) 2016-01-13
PL2964233T3 (pl) 2022-04-25
AU2013381855A1 (en) 2015-10-22
BR112015022070B1 (pt) 2022-01-18
JP2016510738A (ja) 2016-04-11
JP6247708B2 (ja) 2017-12-13
CA2904523C (en) 2024-01-09
BR112015022070A2 (pt) 2017-07-18
EP2964233A4 (en) 2016-10-19
EA201591683A1 (ru) 2016-08-31
EP3978002A1 (en) 2022-04-06
ES2904256T3 (es) 2022-04-04
AU2013381855B2 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
US11351187B2 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20230210880A1 (en) Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events
US8680052B1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US11147879B2 (en) Methods of treating or preventing stent thrombosis
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
CN119816305A (zh) Milvexian在治疗或预防缺血性中风中的用途
HK40073112A (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2014142780A1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2024220809A1 (en) Use of milvexian in the treatment and prevention of thrombotic conditions in patients with cardiovascular or cerebrovascular disease
MX2011005376A (es) Metodo para reducir trombocitopenia y mortalidad asociada a trombocitopenia.
TW202241446A (zh) 治療方法
WO2015054542A1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
Faltas A new anticoagulant for a new era: review of recent data on dabigatran etexilate
Manolis et al. Cardiology News/Recent Literature Review/Third Quarter 2015
TW200409638A (en) Use of MELOXICAM in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073112

Country of ref document: HK